Pharmacokinetics and Toxicokinetics in Drug Development
Pharmacokinetics (PK) and toxicokinetics (TK) are critical components of drug development, providing quantitative data on the absorption, distribution, metabolism, and excretion (ADME) of compounds, as well as their concentration–time profiles related to toxic effects. Understanding PK and TK helps optimize dosing regimens, predict human responses, and assess safety margins.
Pharmacokinetic studies focus on characterizing drug behavior in the body under therapeutic conditions. Parameters such as bioavailability, half-life, volume of distribution, and clearance are measured using plasma and tissue concentration data. These parameters guide dose selection and scheduling to maintain efficacious drug levels.
Toxicokinetics examines the relationship between systemic exposure to a compound and observed toxic effects. It is typically conducted at doses exceeding therapeutic levels in animal models to define thresholds for adverse events. TK data provide insight into accumulation, saturable metabolism, and bioactivation pathways that may contribute to toxicity.
Both PK and TK studies employ techniques like liquid chromatography–mass spectrometry (LC-MS/MS) for sensitive quantitation. Physiologically based pharmacokinetic (PBPK) modeling integrates biological and chemical data to simulate drug disposition in virtual populations, enhancing translational predictions.
Integration of PK and TK data with pharmacodynamics (PD) enables the characterization of dose–response relationships, therapeutic indices, and safety margins. Regulatory submissions require comprehensive PK/TK data packages to support clinical trial initiation and risk assessment.
Advances in bioanalytical methods, in silico modeling, and biomarker identification continue to refine PK/TK understanding, accelerating drug development while minimizing adverse effects.